Insulet Corp. (PODD): Price and Financial Metrics
PODD Price/Volume Stats
| Current price | $166.25 | 52-week high | $335.91 |
| Prev. close | $164.73 | 52-week low | $125.82 |
| Day low | $162.11 | Volume | 844,600 |
| Day high | $167.10 | Avg. volume | 874,459 |
| 50-day MA | $174.51 | Dividend yield | N/A |
| 200-day MA | $191.36 | Market Cap | 11.64B |
PODD Stock Price Chart Interactive Chart >
Insulet Corp. (PODD) Company Bio
A medical device company developing and marketing insulin infusion system. (Source:Wiki)
Latest PODD News From Around the Web
Below are the latest news stories about INSULET CORP that investors may wish to consider to help them evaluate PODD as an investment opportunity.
Here's Why You Should Invest in Insulet (PODD) Stock for NowInvestors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position. |
Bull of the Day: Insulet (PODD)A big earnings beat at the perfect time has this stock up over 50% in short order. |
Top Stock Picks for Week of December 25, 2023An Interesting Bet for Trend Investors and a Leading Medical Products Stock for Your Review |
Here's How Much a $1000 Investment in Insulet Made 10 Years Ago Would Be Worth TodayInvesting in certain stocks can pay off in the long run, especially if you hold on for a decade or more. |
3 Medical-Device Stocks Could Click in 2024Baird is bullish on Boston Scientific, Insulet, and DexCom, stocks set to benefit as those companies ramp up sales. |
PODD Price Returns
| 1-mo | -0.23% |
| 3-mo | -18.69% |
| 6-mo | 13.10% |
| 1-year | -47.93% |
| 3-year | -41.71% |
| 5-year | 101.69% |
| YTD | -23.38% |
| 2023 | -26.30% |
| 2022 | 10.64% |
| 2021 | 4.08% |
| 2020 | 49.32% |
| 2019 | 115.83% |
Continue Researching PODD
Here are a few links from around the web to help you further your research on Insulet Corp's stock as an investment opportunity:Insulet Corp (PODD) Stock Price | Nasdaq
Insulet Corp (PODD) Stock Quote, History and News - Yahoo Finance
Insulet Corp (PODD) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...